Lower ataxia telangiectasia mutated (ATM) mRNA expression is correlated with poor outcome of laryngeal and pharyngeal cancer patients

Annals of Oncology

Volumn 22, Issue 5, 2011, Pages 1088-1093

  Lee, K W ^a,b,c   Tsai, Y S ^d,e   Chiang, F Y ^a,b   Huang, J L ^f   Ho, K Y ^a,b   Yang, Y H ^e   Kuo, W R ^a,b   Chen, M K ^g,h   Lin, C S ^d,e  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^d Department of Otorhinolaryngology Head and Neck Surgery   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^g CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^h CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Ataxia telangiectasia mutated; Laryngeal cancer; Pharyngeal cancer; Survival analysis

Indexed keywords

ATM PROTEIN; MESSENGER RNA;

ADULT; AGE; ARTICLE; CANCER PATIENT; CANCER SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LARYNX CANCER; MALE; OVERALL SURVIVAL; PHARYNX CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR;

EID: 79955495911     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq569     Document Type: Article

References (31)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Friedlander PL. Genomic instability in head and neck cancer patients. Head Neck 2001; 23: 683-691.
3. Bockmuhl U, Schwendel A, Dietel M, Petersen I. Distinct patterns of chromosomal alterations in high- and low-grade head and neck squamous cell carcinomas. Cancer Res 1996; 56: 5325-5329.
4. Veltman JA, Bot FJ, Huynen FC et al. Chromosome instability as an indicator of malignant progression in laryngeal mucosa. J Clin Oncol 2000; 18: 1644-1651.
5. Cheng L, Eicher SA, Guo Z et al. Reduced DNA repair capacity in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 1998; 7: 465-468.
6. Paz-Elizur T, Ben-Yosef R, Elinger D et al. Reduced repair of the oxidative 8-oxoguanine DNA damage and risk of head and neck cancer. Cancer Res 2006; 66: 11683-11689.
7. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004; 73: 39-85.
8. Bose S, Yap LF, Fung M et al. The ATM tumour suppressor gene is downregulated in EBV-associated nasopharyngeal carcinoma. J Pathol 2009; 217: 345-352.
9. Grabsch H, Dattani M, Barker L et al. Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer. Clin Cancer Res 2006; 12: 1494-1500.
10. He Y, Chen Q, Li B. ATM in oral carcinogenesis: association with clinicopathological features. J Cancer Res Clin Oncol 2008; 134: 1013-1020.
11. Kang B, Guo RF, Tan XH et al. Expression status of ataxia-telangiectasia-mutated gene correlated with prognosis in advanced gastric cancer. Mutat Res 2008; 638: 17-25.
12. Xing J, Wu X, Vaporciyan AA et al. Prognostic significance of ataxiatelangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer. Cancer 2008; 112: 2756-2764.
13. Ye C, Cai Q, Dai Q et al. Expression patterns of the ATM gene in mammary tissues and their associations with breast cancer survival. Cancer 2007; 109: 1729-1735.
14. Parikh RA, White JS, Huang X et al. Loss of distal 11q is associated with DNA repair deficiency and reduced sensitivity to ionizing radiation in head and neck squamous cell carcinoma. Genes Chromosomes Cancer 2007; 46: 761-775.
15. Ai L, Vo QN, Zuo C et al. Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol Biomarkers Prev 2004; 13: 150-156.
16. Bolt J, Vo QN, Kim WJ et al. The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms. Oral Oncol 2005; 41: 1013-1020.
17. Chiou SS, Huang JL, Tsai YS et al. Elevated mRNA transcripts of nonhomologous end-joining genes in pediatric acute lymphoblastic leukemia. Leukemia 2007; 21: 2061-2064.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
19. Vo QN, Kim WJ, Cvitanovic L et al. The ATM gene is a target for epigenetic silencing in locally advanced breast cancer. Oncogene 2004; 23: 9432-9437.
20. Brieger J, Jacob R, Riazimand HS et al. Chromosomal aberrations in premalignant and malignant squamous epithelium. Cancer Genet Cytogenet 2003; 144: 148-155.
21. van den Broek GB, Wreesmann VB, van den Brekel MW et al. Genetic abnormalities associated with chemoradiation resistance of head and neck squamous cell carcinoma. Clin Cancer Res 2007; 13: 4386-4391.
22. Lazar AD, Winter MR, Nogueira CP et al. Loss of heterozygosity at 11q23 in squamous cell carcinoma of the head and neck is associated with recurrent disease. Clin Cancer Res 1998; 4: 2787-2793.
23. Handra-Luca A, Hernandez J, Mountzios G et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007; 13: 3855-3859.
24. Yang MH, Chiang WC, Chou TY et al. Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation. Clin Cancer Res 2006; 12: 507-515.
25. Hitt R, Lopez-Pousa A, Martinez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23: 8636-8645.
26. Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-1704.
27. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715.
28. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
29. Helleday T, Petermann E, Lundin C et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8: 193-204.
30. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917.
31. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.